Zhejiang CONBA Pharmaceutical Co., Ltd. Class A

Zhejiang CONBA Pharmaceutical Co., Ltd. Class A

SSSE:600572
4.18
CNY
+0.01
(+0.24%)
0.19EPS
23.96P/E
10.95BMarket Cap
Apr 16Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A carries a market capitalization of 10.95B, placing it among publicly traded companies globally. Its enterprise value stands at 10.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.95B
Enterprise Value10.37B

Important Dates

Zhejiang CONBA Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 16, 2027.

Earnings Date4/16/2027

Share Statistics

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A has 2.54B shares outstanding.

Shares Outstanding2.54B

Valuation Ratios

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 23.96. The price-to-sales ratio is 1.60, and the price-to-book ratio stands at 1.51.

PE Ratio23.96
PS Ratio1.60
PB Ratio1.51
P/TBV Ratio1.63

Enterprise Valuation

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 15.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.37B versus a market cap of 10.95B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.52
EV / EBITDA15.35
EV / EBIT15.35

Financial Position

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.57, indicating elevated leverage, while an interest coverage ratio of 160.55 demonstrates strong ability to service its debt obligations.

Current Ratio1.87
Quick Ratio0.32
Debt / Equity2.57
Debt / EBITDA0.28
Interest Coverage160.55

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 6.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.63 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.93, useful for judging operating efficiency across full business cycles. The company generates approximately 872,454.44 in revenue per employee across its workforce of 7,826.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.73 indicates how many times Zhejiang CONBA Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.49
Return on Assets (ROA)4.50
Return on Invested Capital (ROIC)6.63
Return on Capital Employed (ROCE)5.93
Revenue Per Employee872,454.44
Employee Count7,826.00
Inventory Turnover2.73

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A recorded 170.45M in income tax expense. That works out to an effective tax rate of 26.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 648.60M, leaving 456.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax170.45M
Effective Tax Rate26.28

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A's stock has declined approximately 11.63% over the past 52 weeks. The 50-day moving average sits at 4.29, while the 200-day moving average is 4.34.

52-Week Price Change-11.63%
50-Day Moving Average4.29
200-Day Moving Average4.34

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A generated 6.83B in revenue and converted that into 456.74M in net income, yielding earnings per share of 0.19. EBITDA reached 675.44M, while operating income came in at 819.92M.

Revenue6.83B
Gross Profit3.77B
Operating Income819.92M
Pretax Income648.60M
Net Income456.74M
EBITDA675.44M
EBIT675.44M
Earnings Per Share (EPS)0.19

Balance Sheet

CNY

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A holds 882.42M in cash and equivalents against 189.57M in total debt, resulting in a net debt position of -697.39M. Total book value stands at 7.26B, with working capital of 2.37B providing operational flexibility.

Cash & Cash Equivalents882.42M
Total Debt189.57M
Net Debt-697.39M
Equity (Book Value)7.26B
Book Value Per Share2.86
Working Capital2.37B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-224.28M

Margins

Over the twelve months ended September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A posted a gross margin of 55.19, reflecting its pricing power and cost economics. The operating margin of 12.01 and net profit margin of 6.69 provide insight into operational efficiency.

Gross Margin55.19
Operating Margin12.01
Pretax Margin9.50
Profit Margin6.69
EBITDA Margin9.89

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of 75.48 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang CONBA Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio75.48
Shareholder Yield4.99

Stock Splits

Zhejiang CONBA Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 15, 2016 with a 2:3 split ratio.

Last Split Date6/15/2016
Split Ratio2:3

Scores

As of September 30, 2026, Zhejiang CONBA Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.89